[1] Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Höftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Prüss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostásy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J. A clinical approach to dignosis of autoimmune encephalitis[J]. Lancet Neurol, 2016, 15:391-404.
[2] Corsellis JA, Goldberg GJ, Norton AR. "Limbic encephalitis" and its association with carcinoma[J]. Brain, 1968, 91:481-496.
[3] Ramanathan S, Al-Diwani A, Waters P, Irani SR. The autoantibody-mediated encephalitides:from clinical observations to molecular pathogenesis[J]. J Neurol, 2019.[Epub ahead of print]
[4] Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis:an observational cohort study[J]. Lancet Neurol, 2013, 12:157-165.
[5] Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma[J]. Ann Neurol, 2005, 58:594-604.
[6] Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR. Anti-NMDA-receptor encephalitis:case series and analysis of the effects of antibodies[J]. Lancet Neurol, 2008, 7:1091-1098.
[7] Ma GM, Chow JS, Taylor GA. Review of paraneoplastic syndromes in children[J]. Pediatr Radiol, 2019, 49:534-550.
[8] Damato V, Balint B, Kienzler AK, Irani SR. The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders[J]. Mov Disord, 2018, 33:1376-1389.
[9] Nosadini M, Toldo I, Tascini B, Bien CG, Parmeggiani L, De Gaspari P, Zuliani L, Sartori S. LGI1 and CASPR2 autoimmunity in children:systematic literature review and report of a young girl with Morvan syndrome[J]. J Neuroimmunol, 2019, 335:577008.
[10] Mandel-Brehm C, Dubey D, Kryzer TJ, O'Donovan BD, Tran B, Vazquez SE, Sample HA, Zorn KC, Khan LM, Bledsoe IO, McKeon A, Pleasure SJ, Lennon VA, DeRisi JL, Wilson MR, Pittock SJ. Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis[J]. N Engl J Med, 2019, 381:47-54.
[11] Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M, Roberts K, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R, Graus F, Rudy B, Dalmau J. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels[J]. Ann Neurol, 2013, 73:120-128.
[12] Aoe S, Kokudo Y, Takata T, Kobara H, Yamamoto M, Touge T, Deguchi K, Masaki T. Repeated anti-N-methyl-D-aspartate receptor encephalitis coexisting with anti-myelin oligodendrocyte glycoprotein antibody-associated diseases:a case report[J]. Mult Scler Relat Disord, 2019, 35:182-184.
[13] Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E, Llufriu S, Muchart J, Erro ME, Abraira L, Moris G, Monros-Giménez L, Corral-Corral Í, Montejo C, Toledo M, Bataller L, Secondi G, Ariño H, Martínez-Hernández E, Juan M, Marcos MA, Alsina L, Saiz A, Rosenfeld MR, Graus F, Dalmau J; Spanish Herpes Simplex Encephalitis Study Group. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis:a prospective observational study and retrospective analysis[J]. Lancet Neurol, 2018, 17:760-772.
[14] Nosadini M, Mohammad SS, Corazza F, Ruga EM, Kothur K, Perilongo G, Frigo AC, Toldo I, Dale RC, Sartori S. Herpes simplex virus-induced anti-N-methyl-D-aspartate receptor encephalitis:a systematic literature review with analysis of 43 cases[J]. Dev Med Child Neurol, 2017, 59:796-805.
[15] Magira EE, Alexopoulos H, Charitatos E, Michas D, Dalakas MC. Progressive encephalomyelitis with rigidity and myoclonus (PERM):brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab[J]. Ther Adv Neurol Disord, 2016, 9:69-73.
[16] Mueller S, Färber A, Prüss H, Melzer N, Golombeck KS, Kümpfel T, Thaler F, Elisak M, Lewerenz J, Kaufmann M, Sühs KW, Ringelstein M, Kellinghaus C, Bien CG, Kraft A, Zettl UK, Ehrlich S, Handreka R, Rostásy K, Then Bergh F, Faiss JH, Lieb W, Franke A, Kuhlenb äumer G, Wandinger KP, Leypoldt F; German Network for Research on Autoimmune Encephalitis (GENERATE). Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis[J]. Ann Neurol, 2018, 83:863-869.
[17] Shu Y, Qiu W, Zheng J, Sun X, Yin J, Yang X, Yue X, Chen C, Deng Z, Li S, Yang Y, Peng F, Lu Z, Hu X, Petersen F, Yu X. HLA class Ⅱ allele DRB1*16:02 is associated with anti-NMDAR encephalitis[J]. J Neurol Neurosurg Psychiatry, 2019, 90:652-658.
[18] Van Sonderen A, Roelen DL, Stoop JA, Verdijk RM, Haasnoot GW, Thijs RD, Wirtz PW, Schreurs MW, Claas FH, Sillevis Smitt PA, Titulaer MJ. Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4[J]. Ann Neurol, 2017, 81:193-198.
[19] Planagumà J, Haselmann H, Mannara F, Petit-Pedrol M, Grünewald B, Aguilar E, Röpke L, Martín-García E, Titulaer MJ, Jercog P, Graus F, Maldonado R, Geis C, Dalmau J. Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity[J]. Ann Neurol, 2016, 80:388-400.
[20] Peer M, Prüss H, Ben-Dayan I, Paul F, Arzy S, Finke C. Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis:an observational study[J]. Lancet Psychiatry, 2017, 4:768-774.
[21] Crisp SJ, Dixon CL, Jacobson L, Chabrol E, Irani SR, Leite MI, Leschziner G, Slaght SJ, Vincent A, Kullmann DM. Glycine receptor autoantibodies disrupt inhibitory neurotransmission[J]. Brain, 2019, 142:3398-3410.
[22] Kelley BP, Patel SC, Marin HL, Corrigan JJ, Mitsias PD, Griffith B. Autoimmune encephalitis:pathophysiology and imaging review of an overlooked diagnosis[J]. AJNR Am J Neuroradiol, 2017, 38:1070-1078.
[23] Bacchi S, Franke K, Wewegama D, Needham E, Patel S, Menon D. Magnetic resonance imaging and positron emission tomography in anti-NMDA receptor encephalitis:a systematic review[J]. J Clin Neurosci, 2018, 52:54-59.
[24] Wegner F, Wilke F, Raab P, Tayeb SB, Boeck AL, Haense C, Trebst C, Voss E, Schrader C, Logemann F, Ahrens J, Leffler A, Rodriguez-Raecke R, Dengler R, Geworski L, Bengel FM, Berding G, Stangel M, Nabavi E. Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18 F-fluoro-2-deoxy-D-glucose positron emission tomography[J]. BMC Neurol, 2014, 14:136.
[25] Zhou Q, Zhu X, Meng H, Zhang M, Chen S. Anti-dipeptidyl-peptidase-like protein 6 encephalitis, a rare cause of reversible rapid progressive dementia and insomnia[J]. J Neuroimmunol, 2019, 339:577114.
[26] Lancaster E. The diagnosis and treatment of autoimmune encephalitis[J]. J Clin Neurol, 2016, 12:1-13.
[27] Castellano J, Glover R, Robinson J. Extreme delta brush in NMDA receptor encephalitis[J]. Neurohospitalist, 2017, 7:NP3-4.
[28] Koch H, Niturad CE, Theiss S, Bien CG, Elger C, Wandinger KP, Vincent A, Malter M, Körtvelyessy P, Lerche H, Dihné M. In vitro neuronal network activity as a new functional diagnostic system to detect effects of cerebrospinal fluid from autoimmune encephalitis patients[J]. Sci Rep, 2019, 9:5591.
[29] Lee WJ, Lee ST, Moon J, Sunwoo JS, Byun JI, Lim JA, Kim TJ, Shin YW, Lee KJ, Jun JS, Lee HS, Kim S, Park KI, Jung KH, Jung KY, Kim M, Lee SK, Chu K. Tocilizumab in autoimmune encephalitis refractory to rituximab:an institutional cohort study[J]. Neurotherapeutics, 2016, 13:824-832.
[30] Shin YW, Lee ST, Kim TJ, Jun JS, Chu K. Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis[J]. Ann Clin Transl Neurol, 2018, 5:598-605. |